MESQUITE, NV / ACCESSWIRE / April 10, 2017 / Cannabis Sativa. Inc. (OTCQB: CBDS) announced today that it entered into an agreement to acquire the intellectual property for the White Rabbit brand of cannabis sprays and cannabis mints, www.enjoywhiterabbit.com. The acquisition will include the exclusive and proprietary product formulations, product mixes, manufacturing methods and branding. The White Rabbit product line currently consists of fast acting low dose cannabis oral sprays and popular low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each.

The Company’s President David Tobias stated, “The White Rabbit line of products is very attractive to us given its low dose and metering, which are important qualities for medicinal use.” The White Rabbit products are currently being sold throughout California. Upon closing, the Company will look to license the Cannabis Sativa White Rabbit products for use in states where medical marijuana is legal.

Forward-Looking Statements:

This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company’s success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.